达格列净对急性心肌梗死合并2型糖尿病患者PCI术后心血管事件的影响

bstract] Objective To investigate the effect of daglizin on cardiovascular events in patients with acute myocardial infarction complicated with type 2 diabetes after percutaneous coronary intervention (PCI). Methods A total of 155 patients with acute myocardial infarction complicated with type 2 diabetes admitted to the cardiovascular department of our hospital from January 2021 to December 2022 were selected as the study objects, and were divided into experimental group (n=78) and control group (n=77) by random number method. The control group was given conventional treatment, and the experimental group was treated with dagaglizin on the basis of this treatment. The clinical related indicators, cardiac function indicators, treatment effectiveness and incidence of cardiovascular events were compared between the two groups after treatment. Results Before treatment, there were no significant differences in general conditions and clinical indicators between the two groups (p>0.05). After 6 months of treatment, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), hypersensitive C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2(Lp-PLA2) in both groups were lower than before treatment (p<0.05), and all indexes in the experimental group were significantly lower than those in the control group (p<0.001). Before treatment, there was no significant difference in cardiac function indexes between the two groups. After treatment, left ventricular ejection fraction (LVEF) and 6-minute walking test (6MWT) in the experimental group were significantly higher than those in the control group. Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), amino terminal brain natriuretic peptide precursor (NT-proBNP) and heart rate were significantly lower than those of control group, with statistically significant differences (p<0.001). The total effective rate of all patients was 92.90%, of which the total effective rate of the experimental group was 96.15%, which was significantly higher than that of the control group 89.61%, and the incidence of cardiovascular events in the experimental group (7.69%) was significantly lower than that of the control group (16.88%), with statistically significant differences (p<0.01). Conclusion Daglizin has significant efficacy in lowering blood sugar, improving heart function, improving treatment efficiency and reducing the incidence of cardiovascular events in patients with acute myocardial infarction complicated with type 2 diabetes after PCI, which is worthy of promotion and application in clinical treatment.